Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

Phio will present Phase 1b PH-762 trial data, but no efficacy results are disclosed.

What the company is saying

Phio Pharmaceuticals is announcing a scheduled presentation of clinical data from its Phase 1b trial of PH-762 at the SITC annual meeting, emphasizing the potential of its INTASYL gene silencing technology in skin cancers. The company frames PH-762 as a possible tissue-sparing, neoadjuvant, non-surgical treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Robert Bitterman, President and CEO, asserts that PH-762 could shrink tumors pre-surgery while maintaining safety, positioning the drug as a differentiated option versus current standards. The release highlights that PH-762 was well-tolerated in the Phase 1b study, but does not provide any quantitative safety or efficacy data. The company acknowledges that further studies are required and commits to a Phase 2b trial in the first half of 2027. The tone is optimistic and forward-looking, focusing on potential benefits rather than realised clinical outcomes.

What the data suggests

The announcement confirms completion and presentation of the Phase 1b trial (NCT 06014086) for PH-762, with the presentation scheduled for November 7, 2026 at SITC. The only realised facts are the trial's completion, the upcoming presentation, and the planned Phase 2b study in early 2027. No clinical efficacy, safety, or outcome data are disclosed, and there is no information on response rates, adverse events, or comparative performance versus standard treatments. All claims about PH-762's tolerability, tumor shrinkage, and tissue-sparing potential remain speculative without supporting data. The disclosure is transparent about trial identifiers and event timing but lacks the quantitative detail needed to independently assess the drug's clinical value. No financial figures, cash, or revenue data are provided.

Analysis

The announcement is generally positive in tone, highlighting the completion and presentation of Phase 1b clinical trial results and the planning of a Phase 2b study. However, the majority of key claims are forward-looking, focusing on the potential of PH-762 as a new treatment and its possible benefits, rather than realised clinical outcomes. No specific safety, efficacy, or outcome data are disclosed, and all statements about clinical benefit, tissue-sparing effects, or tumor shrinkage are couched in speculative language ('may', 'potential', 'suggests'). The only realised facts are the completion of the Phase 1b trial and the scheduled presentation. The timeline for any tangible benefit is long-term, with the next clinical milestone (Phase 2b) not expected until 2027. There is no indication of a large capital outlay in this announcement. The gap between narrative and evidence is moderate: the company uses optimistic language about PH-762's promise without providing supporting quantitative data.

Risk flags

• ●The absence of disclosed efficacy or safety data from the Phase 1b trial means investors cannot independently assess PH-762's clinical promise or risk profile. This limits the ability to gauge the likelihood of future trial success or regulatory advancement.
• ●All claims regarding PH-762's benefits are forward-looking and speculative, relying on language such as 'may' and 'potential,' with no quantitative evidence provided. This increases the risk that the drug's actual performance may not meet management's expectations.
• ●The timeline to any commercial or clinical value is extended, with the next study (Phase 2b) not planned until the first half of 2027. This long execution window exposes the company to clinical, regulatory, and funding risks before any value realisation.
• ●No financial data, funding status, or cash runway disclosures are included, leaving investors unable to assess the company's ability to support ongoing development through the next clinical phase.

Bottom line

Phio's announcement signals progress in its PH-762 program by confirming the completion and public presentation of Phase 1b trial results, but it does not provide any clinical data to support claims of efficacy or safety. All positive statements about the drug's potential are speculative and unsupported by disclosed outcomes. The next meaningful milestone—a Phase 2b trial—is at least several months away, with no near-term catalysts or revenue prospects. Investors are left with a narrative of promise but no hard evidence, and must wait for actual clinical data before reassessing the program's value. The most important takeaway is that while the company is advancing its lead asset, the lack of disclosed results means the investment case remains unproven and high risk until further data are released.

Announcement summary

(NASDAQ:PHIO) Phio Pharmaceuticals Corp. announced it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Phoenix, Arizona from November 6-8, 2026. The presentation will be delivered by John Strasswimmer, M.D., Ph.D., lead investigator for the Phase 1b clinical trial, on Saturday, November 7, from 2:45 PM to 3:00 PM at the Phoenix Convention Center, Halls BC, during the Clinical Oral Abstract Session 2. The presentation is titled 'Neoadjuvant Phase 1b Results: Dose Escalation of Intratumoral PH-762 for Cutaneous SCC, Melanoma, or Merkel Cell (NCT 06014086)'. The Phase 1b trial (NCT# 06014086) evaluated the safety and efficacy of INTASYL PH-762 as a neoadjuvant intratumoral injection for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Study findings suggest PH-762 is well-tolerated and may represent a tissue-sparing neoadjuvant to the current cSCC treatment standard of Mohs micrographic surgery (MMS) and/or standard excision. PH-762 is a potential non-surgical treatment for skin cancers. Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals, stated that the growing body of clinical evidence suggests PH-762 may offer a meaningful new treatment option capable of shrinking tumors prior to surgery while maintaining an attractive safety profile. He also stated that these findings support PH-762's potential to become a differentiated, tissue-sparing neoadjuvant treatment that may reduce the burden of surgery while preserving favorable clinical outcomes. Additional studies are needed to further evaluate the safety and efficacy of PH-762, and a Phase 2b study is planned for the first half of 2027. Phio Pharmaceuticals' INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. PH-762 is an INTASYL compound that silences the PD-1 gene implicated in various forms of skin cancer.

Disagree with this article?